Abstract
In this study we report the functional comparison of T cell receptor (TCR)-engineered major histocompatibility complex (MHC) class I-restricted CD4(+)versus CD8(+)T cells targeting a peptide fromsix transmembrane epithelial antigen of the prostate 1(STEAP1) in the context of HLA-A*02:01. STEAP1 is a tumor-associated antigen, which is overexpressed in many cancers, including Ewing sarcoma (EwS). Based on previous observations, we postulated strong antitumor potential of tumor-redirected CD4(+)T cells transduced with an HLA class I-restricted TCR against a STEAP1-derived peptide. We compared CD4(+)T cell populations to their CD8(+)counterparts in vitro using impedance-based xCELLigence and cytokine/granzyme release assays. We further compared antitumor activity of STEAP(130)-TCR transgenic (tg) CD4(+)versus CD8(+)T cells in tumor-bearing xenografted Rag2(-/-)gamma c(-/-)mice. TCR tgCD4(+)T cells showed increased cytotoxic features over time with similar functional avidity compared to tgCD8(+)cells after 5-6 weeks of culture. In vivo, local tumor control was equal. Assessing metastatic organotropism of intraveniously (i.v.) injected tumors, only tgCD8(+)cells were associated with reduced metastases. In this analysis, EwS-redirected tgCD4(+)T cells contribute to local tumor control, but fail to control metastatic outgrowth in a model of xenografted EwS.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
Sprache: | Englisch |
Dokumenten ID: | 87575 |
Datum der Veröffentlichung auf Open Access LMU: | 25. Jan. 2022, 09:24 |
Letzte Änderungen: | 25. Jan. 2022, 09:24 |